Search
We report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PApilloma TRIal against Cancer In young Adults.
We report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PATRICIA (PApilloma TRIal against Cancer In young...
The authors previously reported an increased risk of hospitalisation for acute lower respiratory infection up to age 2 years in children delivered by...
In vitro investigations of human innate immune responses to extracellular bacteria commonly utilise killed preparations in preference to live...
In Australia the 7-valent pneumococcal conjugate vaccine (PCV7) is administered at 2, 4 and 6 months of age, with no booster dose.
Concerns about the risk of inducing immune deviation-associated "neonatal tolerance" as described in mice have restricted the widespread adoption...
Increased numbers of children presenting with febrile adverse events following trivalent influenza vaccine (TIV) were noted in Australia in 2010.
We investigated the genetic and epigenetic regulation of the UBASH3A gene and its association with early-onset sepsis. Using matched whole blood DNA methylation, gene expression, genotypes, and immune cell counts from the EPIC-HIPC newborn cohort, we report that promoter methylation was negatively correlated with ontogenetic changes in UBASH3A gene expression and circulating CD3+ T-cell numbers.
Licensed recombinant protein respiratory syncytial virus (RSV) vaccines can prevent substantial morbidity in older adults. However, revaccination to prevent waning protection may be suboptimal, prompting the exploration of candidates for heterologous boosting. In this clinical trial of RSV vaccine-naive older adults, we evaluated SCB-1019T, a novel unadjuvanted bivalent RSV prefusion F (preF) protein vaccine stabilized via Trimer-Tag technology, in comparison to the licensed AS01E-adjuvanted RSV vaccine Arexvy.
Influenza vaccines are important for reducing the burden of influenza, particularly for populations at risk of more severe infections. Obesity is associated with increased influenza severity and therefore individuals with obesity are often specifically recommended for annual influenza vaccination. Obesity is also associated with an altered inflammatory profile, which may influence vaccine responses. This systematic review aimed to evaluate the evidence for any association between obesity and influenza vaccine immunogenicity.